{
  "usdmVersion": "4.0",
  "generatedAt": "2026-01-02T19:35:54.340415",
  "generator": "Protocol2USDM v6.5.0",
  "study": {
    "id": "study_1",
    "instanceType": "Study",
    "versions": [
      {
        "id": "sv_1",
        "instanceType": "StudyVersion",
        "versionIdentifier": "1.0",
        "studyDesigns": [
          {
            "id": "sd_1",
            "name": "Study Design",
            "rationale": "Protocol-defined study design for investigating efficacy and safety",
            "instanceType": "InterventionalStudyDesign",
            "population": {
              "id": "pop_1",
              "instanceType": "StudyDesignPopulation",
              "name": "Study Population",
              "description": "Target population for the study as defined by eligibility criteria",
              "includesHealthySubjects": false
            },
            "model": {
              "id": "code_model_1",
              "code": "C82638",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Single Group Study",
              "instanceType": "Code"
            },
            "indications": [
              {
                "id": "ind_1",
                "name": "Wilson Disease",
                "isRareDisease": false,
                "instanceType": "Indication",
                "description": "Participants with Wilson Disease"
              }
            ]
          }
        ],
        "titles": [
          {
            "id": "title_1",
            "text": "A Phase 2, Open-label Study to Assess Copper and Molybdenum Balance in Participants with Wilson Disease Treated with ALXN1840",
            "type": {
              "code": "Official Study Title",
              "codeSystem": "USDM",
              "decode": "Official Study Title"
            },
            "instanceType": "StudyTitle"
          },
          {
            "id": "title_2",
            "text": "Copper and Molybdenum Balance in Participants with Wilson Disease Treated with ALXN1840",
            "type": {
              "code": "Brief Study Title",
              "codeSystem": "USDM",
              "decode": "Brief Study Title"
            },
            "instanceType": "StudyTitle"
          }
        ],
        "studyIdentifiers": [
          {
            "id": "sid_1",
            "text": "ALXN1840-WD-204",
            "scopeId": "org_unknown",
            "instanceType": "StudyIdentifier"
          },
          {
            "id": "sid_2",
            "text": "2020-001104-41",
            "scopeId": "org_unknown",
            "instanceType": "StudyIdentifier"
          },
          {
            "id": "sid_3",
            "text": "119006",
            "scopeId": "org_unknown",
            "instanceType": "StudyIdentifier"
          },
          {
            "id": "sid_4",
            "text": "NCT04573309",
            "scopeId": "org_unknown",
            "instanceType": "StudyIdentifier"
          }
        ],
        "organizations": [
          {
            "id": "org_1",
            "name": "Alexion Pharmaceuticals, Inc.",
            "type": {
              "code": "Pharmaceutical Company",
              "codeSystem": "USDM",
              "decode": "Pharmaceutical Company"
            },
            "instanceType": "Organization"
          }
        ],
        "studyPhase": {
          "code": "Phase2",
          "codeSystem": "USDM",
          "decode": "Phase2"
        },
        "studyInterventions": [
          {
            "id": "int_1",
            "name": "ALXN1840",
            "role": {
              "code": "Investigational Product",
              "codeSystem": "USDM",
              "decode": "Investigational Product"
            },
            "instanceType": "StudyIntervention",
            "description": "A novel copper binding agent (bis-choline tetrathiomolybdate) in development for the treatment of Wilson disease (WD).",
            "productIds": [
              "prod_1"
            ],
            "administrationIds": [
              "admin_1"
            ]
          },
          {
            "id": "int_2",
            "name": "Paracetamol/acetaminophen",
            "role": {
              "code": "Concomitant Medication",
              "codeSystem": "USDM",
              "decode": "Concomitant Medication"
            },
            "instanceType": "StudyIntervention",
            "description": "Permitted for use as an exception with the approval of the Investigator.",
            "administrationIds": [
              "admin_2"
            ]
          },
          {
            "id": "int_3",
            "name": "Ibuprofen",
            "role": {
              "code": "Concomitant Medication",
              "codeSystem": "USDM",
              "decode": "Concomitant Medication"
            },
            "instanceType": "StudyIntervention",
            "description": "Permitted for use with caution and approval of the Investigator.",
            "administrationIds": [
              "admin_3"
            ]
          }
        ],
        "administrableProducts": [
          {
            "id": "prod_1",
            "name": "ALXN1840",
            "instanceType": "AdministrableProduct",
            "doseForm": {
              "code": "Tablet",
              "codeSystem": "USDM",
              "decode": "Tablet"
            },
            "strength": "15 mg",
            "substanceIds": [
              "sub_1"
            ],
            "manufacturer": "Alexion"
          }
        ],
        "narrativeContentItems": [
          {
            "id": "nci_1_1",
            "name": "Synopsis",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.1",
            "sectionTitle": "Synopsis"
          },
          {
            "id": "nci_1_2",
            "name": "Schema",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.2",
            "sectionTitle": "Schema"
          },
          {
            "id": "nci_1_3",
            "name": "Schedule of Activities (SoA)",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "1.3",
            "sectionTitle": "Schedule of Activities (SoA)"
          },
          {
            "id": "nci_2_1",
            "name": "Study Rationale",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "2.1",
            "sectionTitle": "Study Rationale"
          },
          {
            "id": "nci_2_2",
            "name": "Background",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "2.2",
            "sectionTitle": "Background"
          },
          {
            "id": "nci_2_3",
            "name": "Benefit-Risk Assessment",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "2.3",
            "sectionTitle": "Benefit-Risk Assessment"
          },
          {
            "id": "nci_4_1",
            "name": "Overall Design",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.1",
            "sectionTitle": "Overall Design"
          },
          {
            "id": "nci_4_2",
            "name": "Scientific Rationale for Study Design",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.2",
            "sectionTitle": "Scientific Rationale for Study Design"
          },
          {
            "id": "nci_4_3",
            "name": "Justification for Dose",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.3",
            "sectionTitle": "Justification for Dose"
          },
          {
            "id": "nci_4_4",
            "name": "End of Study Definition",
            "text": "",
            "order": 3,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.4",
            "sectionTitle": "End of Study Definition"
          },
          {
            "id": "nci_5_1",
            "name": "Inclusion Criteria",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "5.1",
            "sectionTitle": "Inclusion Criteria"
          },
          {
            "id": "nci_5_2",
            "name": "Exclusion Criteria",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "5.2",
            "sectionTitle": "Exclusion Criteria"
          },
          {
            "id": "nci_5_3",
            "name": "Lifestyle Considerations",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "5.3",
            "sectionTitle": "Lifestyle Considerations"
          },
          {
            "id": "nci_5_4",
            "name": "Screen Failures",
            "text": "",
            "order": 3,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "5.4",
            "sectionTitle": "Screen Failures"
          },
          {
            "id": "nci_10_1",
            "name": "Definition of AE",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "10.3.1",
            "sectionTitle": "Definition of AE"
          },
          {
            "id": "nci_10_2",
            "name": "Definition of SAE",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "10.3.2",
            "sectionTitle": "Definition of SAE"
          },
          {
            "id": "nci_10_3",
            "name": "Recording and Follow-Up of AE and/or SAE",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "10.3.3",
            "sectionTitle": "Recording and Follow-Up of AE and/or SAE"
          },
          {
            "id": "nci_10_4",
            "name": "Reporting of SAEs",
            "text": "",
            "order": 3,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "10.3.4",
            "sectionTitle": "Reporting of SAEs"
          },
          {
            "id": "nci_11_1",
            "name": "Definitions and Contraceptive Guidance",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "10.4.1",
            "sectionTitle": "Definitions and Contraceptive Guidance"
          },
          {
            "id": "nci_11_2",
            "name": "Collection of Pregnancy Information",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "10.4.2",
            "sectionTitle": "Collection of Pregnancy Information"
          }
        ],
        "abbreviations": [
          {
            "id": "abbr_1",
            "abbreviatedText": "SoA",
            "expandedText": "Schedule of Activities",
            "instanceType": "Abbreviation"
          },
          {
            "id": "abbr_2",
            "abbreviatedText": "SARS-CoV-2",
            "expandedText": "Coronavirus",
            "instanceType": "Abbreviation"
          },
          {
            "id": "abbr_3",
            "abbreviatedText": "AE",
            "expandedText": "Adverse Event",
            "instanceType": "Abbreviation"
          },
          {
            "id": "abbr_4",
            "abbreviatedText": "SAE",
            "expandedText": "Serious Adverse Event",
            "instanceType": "Abbreviation"
          },
          {
            "id": "abbr_5",
            "abbreviatedText": "COVID-19",
            "expandedText": "Coronavirus (SARS-CoV-2) Disease 2019",
            "instanceType": "Abbreviation"
          },
          {
            "id": "abbr_6",
            "abbreviatedText": "WD",
            "expandedText": "Wilson disease",
            "instanceType": "Abbreviation"
          },
          {
            "id": "abbr_7",
            "abbreviatedText": "ADME",
            "expandedText": "absorption, distribution, metabolism, and excretion",
            "instanceType": "Abbreviation"
          },
          {
            "id": "abbr_8",
            "abbreviatedText": "PK",
            "expandedText": "plasma pharmacokinetics",
            "instanceType": "Abbreviation"
          },
          {
            "id": "abbr_9",
            "abbreviatedText": "NCC",
            "expandedText": "non-ceruloplasmin-bound copper",
            "instanceType": "Abbreviation"
          },
          {
            "id": "abbr_10",
            "abbreviatedText": "NCCcorrected",
            "expandedText": "non-ceruloplasmin-bound copper corrected",
            "instanceType": "Abbreviation"
          },
          {
            "id": "abbr_11",
            "abbreviatedText": "TPC",
            "expandedText": "tetrathiomolybdate- copper -albumin tripartite complex",
            "instanceType": "Abbreviation"
          }
        ],
        "amendments": [
          {
            "id": "amend_1",
            "number": "1",
            "scope": {
              "code": "Global",
              "codeSystem": "USDM",
              "decode": "Global"
            },
            "instanceType": "StudyAmendment",
            "summary": "The main reason for preparation of this amendment was to update procedures outlined in the Schedule of Activities, remove contradictory text on the reporting of serious adverse events, and add details of an interim analysis.",
            "effectiveDate": "2020-08-18",
            "reasonIds": [
              "ar_1_1",
              "ar_1_2",
              "ar_1_3"
            ],
            "previousVersion": "Original Protocol",
            "newVersion": "1"
          },
          {
            "id": "amend_2",
            "number": "2",
            "scope": {
              "code": "Global",
              "codeSystem": "USDM",
              "decode": "Global"
            },
            "instanceType": "StudyAmendment",
            "summary": "The main reason for preparation of this amendment was to revise the exclusion criterion for a urine drug screen. Changes implemented via Administrative Letter 1 and Administrative Letter 2, as well as COVID vaccination guidance, have also been incorporated.",
            "effectiveDate": "2021-03-19",
            "reasonIds": [
              "ar_2_1",
              "ar_2_2",
              "ar_2_3"
            ],
            "previousVersion": "1",
            "newVersion": "2"
          },
          {
            "id": "amend_3",
            "number": "3",
            "scope": {
              "code": "Global",
              "codeSystem": "USDM",
              "decode": "Global"
            },
            "instanceType": "StudyAmendment",
            "summary": "The main reason for preparation of this amendment was to update the washout period for zinc.",
            "effectiveDate": "2021-08-31",
            "reasonIds": [
              "ar_3_1",
              "ar_3_2"
            ],
            "previousVersion": "2",
            "newVersion": "3"
          },
          {
            "id": "amend_4",
            "number": "3.1 (US)",
            "scope": {
              "code": "Global",
              "codeSystem": "USDM",
              "decode": "Global"
            },
            "instanceType": "StudyAmendment",
            "summary": "The main reason for preparation of this amendment was to clarify study procedures occurring across different sites in the US, so as to facilitate participant recruitment across different regions of the US, and to lessen inconvenience for participants without compromising the quality of the study.",
            "effectiveDate": "2022-03-18",
            "reasonIds": [
              "ar_4_1"
            ],
            "previousVersion": "3",
            "newVersion": "3.1 (US)"
          }
        ],
        "conditions": [
          {
            "id": "cond_1",
            "name": "ALT Elevation (Moderate)",
            "instanceType": "Condition",
            "description": "ALT is greater than 3 times and less than or equal to 5 times the upper limit of normal.",
            "text": "ALT > 3 × ULN and ≤ 5 × ULN"
          },
          {
            "id": "cond_2",
            "name": "ALT Elevation (Severe)",
            "instanceType": "Condition",
            "description": "ALT is greater than 5 times the upper limit of normal.",
            "text": "ALT > 5 × ULN"
          },
          {
            "id": "cond_3",
            "name": "Low Hemoglobin",
            "instanceType": "Condition",
            "description": "Hemoglobin is less than 10 g/dL.",
            "text": "Hemoglobin < 10 g/dL"
          },
          {
            "id": "cond_4",
            "name": "Low Platelets",
            "instanceType": "Condition",
            "description": "Platelets are less than 100,000/mm3.",
            "text": "Platelets < 100,000/mm3"
          },
          {
            "id": "cond_5",
            "name": "Neutropenia",
            "instanceType": "Condition",
            "description": "Neutrophils decrease more than 30% from baseline and are below the reference range.",
            "text": "Neutrophils > 30% ↓ from baseline AND Neutrophils below reference range at baseline"
          },
          {
            "id": "cond_6",
            "name": "Potential Liver Injury",
            "instanceType": "Condition",
            "description": "Bilirubin is greater than 2 times ULN accompanied by ALT greater than 3 times ULN.",
            "text": "Bilirubin > 2 × ULN Accompanied by ALT > 3 × ULN, indicative of liver injury"
          },
          {
            "id": "cond_7",
            "name": "Neurologic Worsening",
            "instanceType": "Condition",
            "description": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment.",
            "text": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment"
          },
          {
            "id": "cond_8",
            "name": "Psychiatric Worsening",
            "instanceType": "Condition",
            "description": "Evidence of clinically significant acute psychiatric worsening.",
            "text": "Evidence of clinically significant acute psychiatric worsening which may include but not limited to suicidality, acute depression, or psychosis."
          },
          {
            "id": "cond_9",
            "name": "Safety Concern Preventing Titration",
            "instanceType": "Condition",
            "description": "Safety concerns that, in the opinion of the Investigator(s) and/or Alexion, may place participants at undue risk for dose increase.",
            "text": "unless there are safety concerns that, in the opinion of the Investigator(s) and/or Alexion, may place participants at undue risk"
          },
          {
            "id": "cond_10",
            "name": "Serious Hypersensitivity Reaction",
            "instanceType": "Condition",
            "description": "Occurrence of a serious hypersensitivity reaction.",
            "text": "Serious hypersensitivity reaction"
          },
          {
            "id": "cond_11",
            "name": "Severe Uncontrolled Infection",
            "instanceType": "Condition",
            "description": "Occurrence of a severe uncontrolled infection.",
            "text": "Severe uncontrolled infection"
          },
          {
            "id": "cond_12",
            "name": "Use of Disallowed Medication",
            "instanceType": "Condition",
            "description": "Participant uses a disallowed medication.",
            "text": "Use of disallowed medication"
          },
          {
            "id": "cond_13",
            "name": "Pregnancy",
            "instanceType": "Condition",
            "description": "Participant becomes pregnant or plans to become pregnant.",
            "text": "Pregnancy or planned pregnancy"
          }
        ]
      }
    ]
  },
  "administrations": [
    {
      "id": "admin_1",
      "name": "ALXN1840 initial dose",
      "instanceType": "Administration",
      "dose": "15 mg",
      "doseFrequency": "once daily",
      "route": {
        "code": "Oral",
        "codeSystem": "USDM",
        "decode": "Oral"
      },
      "duration": "Approximately 28 days (Day 1 through Day 28)"
    },
    {
      "id": "admin_2",
      "name": "ALXN1840 dose titration",
      "instanceType": "Administration",
      "dose": "30 mg",
      "doseFrequency": "once daily",
      "route": {
        "code": "Oral",
        "codeSystem": "USDM",
        "decode": "Oral"
      },
      "duration": "From Day 29 through Day 39"
    },
    {
      "id": "admin_3",
      "name": "ALXN1840 dose modification",
      "instanceType": "Administration",
      "dose": "15 mg",
      "doseFrequency": "every other day",
      "route": {
        "code": "Oral",
        "codeSystem": "USDM",
        "decode": "Oral"
      },
      "duration": "Dose reduction for management of specific adverse events until resolution."
    },
    {
      "id": "admin_4",
      "name": "Paracetamol/acetaminophen administration",
      "instanceType": "Administration",
      "dose": "maximum 1000 mg",
      "doseFrequency": "per day",
      "route": {
        "code": "Oral",
        "codeSystem": "USDM",
        "decode": "Oral"
      },
      "duration": "As needed with investigator approval"
    },
    {
      "id": "admin_5",
      "name": "Ibuprofen administration",
      "instanceType": "Administration",
      "dose": "not to exceed 1200 mg",
      "doseFrequency": "in any 24-hour period",
      "route": {
        "code": "Oral",
        "codeSystem": "USDM",
        "decode": "Oral"
      },
      "duration": "As needed with investigator approval"
    }
  ],
  "substances": [
    {
      "id": "sub_1",
      "name": "bis-choline tetrathiomolybdate",
      "instanceType": "Substance",
      "description": "Active pharmaceutical ingredient of ALXN1840, formerly known as WTX101. Each 15 mg tablet contains 7.8 mg of tetrathiomolybdic acid."
    }
  ],
  "studyDefinitionDocument": {
    "id": "sdd_1",
    "name": "A Phase 2, Open-label Study to Assess Copper and Molybdenum Balance in Participants with Wilson Disease Treated with ALXN1840",
    "documentType": "Protocol",
    "language": "en",
    "instanceType": "StudyDefinitionDocument",
    "version": "3.1",
    "versionDate": "2022-03-18",
    "contentIds": [
      "nc_1",
      "nc_2",
      "nc_3",
      "nc_4",
      "nc_5",
      "nc_6",
      "nc_7",
      "nc_8",
      "nc_9",
      "nc_10",
      "nc_11",
      "nc_12",
      "nc_13",
      "nc_14",
      "nc_15"
    ]
  },
  "geographicScope": {
    "id": "geo_1",
    "name": "Study Geographic Scope",
    "scopeType": "Multinational",
    "instanceType": "GeographicScope",
    "countryIds": [
      "country_1",
      "country_2"
    ],
    "regions": [
      "North America",
      "Europe"
    ]
  },
  "countries": [
    {
      "id": "country_1",
      "name": "United States",
      "instanceType": "Country",
      "code": "US"
    },
    {
      "id": "country_2",
      "name": "United Kingdom",
      "instanceType": "Country",
      "code": "GB"
    }
  ],
  "transitionRules": [
    {
      "id": "trans_1",
      "name": "Dose Titration to 30mg",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "fromElementId": "dose_15mg",
      "toElementId": "dose_30mg",
      "text": "Following the Run-in Period, participants will be administered ALXN1840 at 15 mg/day for a treatment period of approximately 28 days followed by titration up to 30 mg/day on Day 29."
    },
    {
      "id": "trans_2",
      "name": "Dose Reduction for Moderate ALT Elevation",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "If ALT > 3 × ULN and ≤ 5 × ULN, reduce dose to previous dose level or 15 mg QOD if on 15 mg QD."
    },
    {
      "id": "trans_3",
      "name": "Dose Interruption for Severe ALT Elevation",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "If ALT > 5 × ULN, temporary interruption of dosing."
    },
    {
      "id": "trans_4",
      "name": "Dose Reduction for Low Hemoglobin",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "If Hemoglobin < 10 g/dL, reduce dose to previous dose level or 15 mg QOD if on 15 mg QD."
    },
    {
      "id": "trans_5",
      "name": "Dose Reduction for Low Platelets",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "If Platelets < 100,000/mm3, reduce dose to previous dose level or 15 mg QOD if on 15 mg QD."
    },
    {
      "id": "trans_6",
      "name": "Dose Reduction for Neutropenia",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "If Neutrophils > 30% decrease from baseline and below reference range, reduce dose to previous dose level or 15 mg QOD if on 15 mg QD."
    },
    {
      "id": "trans_7",
      "name": "Dose Interruption for Potential Liver Injury",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "If Bilirubin > 2 × ULN and ALT > 3 × ULN, temporary interruption of dosing."
    },
    {
      "id": "trans_8",
      "name": "Dose Modification for Neurologic Worsening",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "Investigator and Alexion Medical Monitor will evaluate the need for dose modification (interruption, increase or decrease) based on copper control parameters and relevant clinical data."
    },
    {
      "id": "trans_9",
      "name": "Maintain 15mg Dose",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "participants may remain on the 15 mg/day dose for the duration of the study if there are safety concerns."
    },
    {
      "id": "trans_10",
      "name": "Discontinuation for Hypersensitivity",
      "instanceType": "TransitionRule",
      "transitionType": "Discontinuation",
      "text": "Participants must be considered for discontinuation from study intervention if a Serious hypersensitivity reaction occurs."
    },
    {
      "id": "trans_11",
      "name": "Discontinuation for Infection",
      "instanceType": "TransitionRule",
      "transitionType": "Discontinuation",
      "text": "Participants must be considered for discontinuation from study intervention if a Severe uncontrolled infection occurs."
    },
    {
      "id": "trans_12",
      "name": "Discontinuation for Disallowed Medication",
      "instanceType": "TransitionRule",
      "transitionType": "Discontinuation",
      "text": "Participants must be considered for discontinuation from study intervention for Use of disallowed medication."
    },
    {
      "id": "trans_13",
      "name": "Discontinuation for Pregnancy",
      "instanceType": "TransitionRule",
      "transitionType": "Discontinuation",
      "text": "Participants must be considered for discontinuation from study intervention for Pregnancy or planned pregnancy."
    }
  ],
  "computationalExecution": {
    "ready": true,
    "supportedSystems": [
      "EDC",
      "ePRO",
      "CTMS",
      "RTSM"
    ],
    "validationStatus": "pending"
  }
}